AVPR1B and major depressive disorder: However, further drug development is still ongoing and recent clinical outcomes with at least two other V1b antagonists (TS-121 and ABT-436) are promising, showing tendencies to reduce the depression scores of patients with major depressive disorder at doses that attenuate HPA axis hyperactivity or block the pituitary V1b receptor [31,32].